Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Shareholders held by Teva Pharmaceutical Industries Limited on May 28, 2026. The filing details the outcomes of shareholder votes regarding board composition, executive compensation, and the appointment of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance data.
Material Changes and Voting Results
Shareholders voted on three primary matters at the Annual Meeting:
- Board Election: Dr. Sol J. Barer was elected to the Board of Directors to serve until the 2029 annual meeting.
- For: 627,816,662
- Against: 245,921,571
- Abstain: 530,682
- Broker non-votes: 50,661,570
- Executive Compensation (Say-on-Pay): Shareholders approved, on a non-binding advisory basis, the compensation for named executive officers.
- For: 795,976,042
- Against: 77,082,847
- Abstain: 1,170,026
- Broker non-votes: 50,661,570
- Auditor Appointment: Shareholders approved the appointment of Kesselman & Kesselman (a member of PricewaterhouseCoopers International Ltd.) as the independent registered public accounting firm until the 2027 annual meeting.
- For: 880,542,242
- Against: 36,085,507
- Abstain: 525,382
- Broker non-votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document is limited to the procedural results of the shareholder vote.
Investor Verification Checklist
- Verify the tenure of the newly elected board member, Dr. Sol J. Barer, which extends to the 2029 annual meeting.
- Confirm the appointment of Kesselman & Kesselman as the independent auditor through the 2027 annual meeting.
- Note the significant number of broker non-votes (50,661,570) on the board election and executive compensation proposals.
- Review the full proxy statement for details on the specific executive compensation packages approved by shareholders.